We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of ...

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Fintel reports that on October 16, 2024, Raymond James upgraded their outlook for Wave Life Sciences (NasdaqGM:WVE) from ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The ...

In terms of liquidity and interest, the mean open interest for WAVE Life Sciences options trades today is 608.71 with a total ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing ...

US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase ...

RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...